Micro-Leads

Micro-Leads is pioneering next-generation, closed-loop neuromodulation with a focus on high-resolution, minimally-invasive devices. Its core platform integrates smart programmable electrodes, shape-memory percutaneous arrays, and custom application-specific integrated circuits (ASICs) to enable precise neural interfacing for chronic pain, sensory-motor paralysis, and other neurological disorders. The company is in the clinical development stage, positioning its technology as a potential solution for patients who have exhausted existing therapeutic options. Its innovative approach seeks to move neuromodulation from a broad, low-resolution intervention to a targeted, personalized medicine.

Closed-loop neuromodulation platform featuring smart programmable electrodes with embedded electronics, shape-memory percutaneous electrode arrays, and custom ASICs for high-resolution neural sensing and stimulation.

Micro-Leads competes in the neuromodulation space against large, well-capitalized public companies like Medtronic, Boston Scientific, and Abbott, which market traditional open-loop, lower-resolution systems. It also faces potential competition from other neurotechnology startups developing high-channel-count BCIs and closed-loop systems, though its focus on minimally-invasive, percutaneous delivery and integrated ASICs may differentiate its approach.